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Abstract
Background: The three sub-species of Trypanosoma brucei are important pathogens of sub-Saharan Africa. T. b. brucei is
unable to infect humans due to sensitivity to trypanosome lytic factors (TLF) 1 and 2 found in human serum. T. b.
rhodesiense and T. b. gambiense are able to resist lysis by TLF. There are two distinct sub-groups of T. b. gambiense that differ
genetically and by human serum resistance phenotypes. Group 1 T. b. gambiense have an invariant phenotype whereas
group 2 show variable resistance. Previous data indicated that group 1 T. b. gambiense are resistant to TLF-1 due in-part to
reduced uptake of TLF-1 mediated by reduced expression of the TLF-1 receptor (the haptoglobin-hemoglobin receptor
(HpHbR)) gene. Here we investigate if this is also true in group 2 parasites.
Methodology: Isogenic resistant and sensitive group 2 T. b. gambiense were derived and compared to other T. brucei
parasites. Both resistant and sensitive lines express the HpHbR gene at similar levels and internalized fluorescently labeled
TLF-1 similar fashion to T. b. brucei. Both resistant and sensitive group 2, as well as group 1 T. b. gambiense, internalize
recombinant APOL1, but only sensitive group 2 parasites are lysed.
Conclusions: Our data indicate that, despite group 1 T. b. gambiense avoiding TLF-1, it is resistant to the main lytic
component, APOL1. Similarly group 2 T. b. gambiense is innately resistant to APOL1, which could be based on the same
mechanism. However, group 2 T. b. gambiense variably displays this phenotype and expression does not appear to correlate
with a change in expression site or expression of HpHbR. Thus there are differences in the mechanism of human serum
resistance between T. b. gambiense groups 1 and 2.
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Introduction
Trypanosoma brucei is an important parasite of sub-Saharan
Africa. The species is commonly divided into three distinct sub-
species that differ in geographical distribution, host range and the
disease they cause. T. b. brucei is the most widespread form of the
parasite, infecting a wide range of mammals, but is not able to
infect humans because it is susceptible to trypanosome lytic factors
(TLF) found in normal human serum [1]. T. b. gambiense and T. b.
rhodesiense are, in contrast, resistant to lysis by human serum and so
are able to infect humans. The West African trypanosome T. b.
gambiense is the most prevalent form of the human-infective parasite
and is responsible for greater than 90% of reported African
sleeping sickness cases [2]. An important facet of African
trypanosome biology is that the adaptive immune response of
vertebrates is rendered largely ineffective due to the parasite’s
ability to cyclically evade the immune response by changing the
variable surface glycoprotein (VSG) antigens on the cell surface
[3,4]. Several primates, including humans, therefore rely on innate
immunity to prevent infection in the form of TLFs in serum that
kill most species of trypanosome [5,6,7].
There are two distinct forms of TLF particle (TLF-1 and 2) in
human serum. TLF-1 is a member of the high density lipoprotein
(HDL) family of particles [8,9] while TLF-2 is a related high
molecular weight serum protein binding complex [10]. Consider-
able effort and much debate has been focused on determining the
cytotoxic component of these TLFs, predominantly focusing on
TLF-1 due to the difficulty of obtaining active TLF-2 [10].
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Investigation has centered on two primate-specific proteins found
in TLF; haptoglobin-related protein (HPR) and apolipoprotein L1
(APOL1). While there has been some controversy concerning the
roles of these two proteins, the current consensus is that both
proteins are necessary for optimal lysis and that HPR and APOL1
have complementary roles [11,12]. HPR is the ligand that
facilitates uptake of TLF-1 via a parasite haptoglobin-hemoglobin
receptor (HpHbR) [13,14] and it has also been shown to have
some trypanosome specific toxicity [15], possibly due to an un-
cleaved signal peptide that affects membrane fluidity [16]. After
internalization, the TLF-1 particle is then trafficked to the
lysosome where APOL1 is activated by a pH-mediated confor-
mational change to form pores in the lysosome membrane. This
leads to perturbation of the osmotic balance of the organelle and
subsequent lysis [17,18]. As both HPR and APOL1 are found in
TLF-2, it is likely that the lysis method of this particle involves
both of these proteins, although the method of entry for TLF-2
does not directly involve the HpHbR receptor [13,19].
The two human infective trypanosome sub-species have evolved
counter-measures to overcome the innate defense factors.
Understanding the mechanism of how these parasites resist lysis
may lead to the development of new treatment strategies. For
example, the resistance mechanism for T. b. rhodesiense is dependent
upon the expression of a serum resistance associated (SRA) gene.
This has led to new diagnostic techniques [20] and therapeutic
possibilities targeting SRA [21,22]. The SRA gene has not been
found in any T. b. gambiense isolates however [23,24,25], so an
alternate and still unknown mechanism of human serum resistance
exists in this subspecies.
A complicating factor is that T. b. gambiense possesses two distinct
‘‘groups’’ that differ in genotype and phenotype. Isoenzyme and
molecular data show that group 1 and group 2 T. b. gambiense
populations are reliably distinguishable from each other, and that
group 2 is more akin to T. b. brucei than group 1 T. b. gambiense
[26,27,28,29,30,31,32,33,34,35]. In group 1 T. b. gambiense, human
serum resistance is a stable trait [31,33] and it has been suggested
that a reduced uptake of TLF-1 may be partially responsible for
resistance. These parasites exhibit reduced expression of HbHpR,
which may contribute to their ability to infect humans by avoiding
TLF-1 [36]. In addition, mutant or transgenic T. b. brucei lines with
reduced expression of the HpHbR receptor gene are resistant to
TLF-1 particles [13,36], although these lines are still lysed by
normal human serum and TLF-2. This raises the possibility that
group 1 T. b. gambiense parasites are sensitive to APOL1 and that
they avoid lysis by failing to take up APOL1 whether it is in TLF-1
or 2. However, uptake of TLF-2 in these parasites has not so far
been examined. In contrast, group 2 T. b. gambiense exhibit a
variable human serum resistance phenotype in a manner
superficially similar to T. b. rhodesiense, raising the question: do
groups 1 and 2 T. b. gambiense share a common mechanism of
human serum resistance? To address this question we have
compared the properties of the human serum resistance
phenotypes of group 1 and group 2 T. b. gambiense by examining
the effects and uptake of both TLF-1 and recombinant APOL1 in
these parasites.
Methods
T. b. gambiense, T. b. brucei and T. b. rhodesiense cell lines
The human serum resistant group 2 T. b. gambiense strain
STIB386 was originally isolated in 1978 from an infected patient
in the Ivory Coast. ELIANE is a group 1 T. b. gambiense strain
isolated from a human infected while in Coˆte d’Ivoire in 1952
[37]. STIB247 is a human serum sensitive T. b. brucei clone, first
isolated from a hartebeest in Serengeti in 1971 and the T. b.
rhodesiense strain Baganzi was isolated from a human in South-
Eastern Uganda in 1990. All lines were maintained in vitro in
HMI9 medium [38] supplemented by 1.5 mM glucose, 1 mM
methyl cellulose, 250 mM adenosine, 150 mM guanosine and 20%
serum (fetal bovine serum (FBS) for T. b. brucei and sensitive group
2 T. b. gambiense or human serum for the other strains) . All lines
were regularly assayed for human serum sensitivity/resistance.
Human serum resistance & APOL1 assays
Trypanosomes were diluted to 106 per ml in modified HMI9
and incubated in 25% human serum or FBS in a 1 ml volume in a
standard 24 well plate. The numbers of cells in each well were
counted with a hemocytometer for the zero time point. The cells
were incubated with 5% CO2 at 37uC and the number of viable
motile trypanosomes in each well at 6 hours was quantified by
microscopy using a hemocytometer and the percentage of viable
cells calculated compared to time zero.
For the APOL1 lysis assays, a dilution series of recombinant
APOL1 (5–50 mg/ml) was formulated that and made up to equal
volumes with protein free buffer (0.2 M acetic acid and 0.05%
Tween20). A control containing an equal volume of buffer was
also prepared. Each protein volume and the control were
aliquoted into different wells and the cells incubated with 5%
CO2 at 37uC in HMI9 medium containing 25% FBS. The
number of viable motile trypanosomes in each well was recorded
at 24 hours and compared to the control wells containing no
APOL1 to determine percentage survival. In each assay, cells were
incubated in 25% normal human serum as a positive control.
Generation of recombinant APOL1
An Invitrogen GatewayH-compatible entry vector containing
the APOL1 open reading frame (ORF) (Genecopoeia Inc, USA)
was used in conjunction with the Invitrogen GatewayH expression
system. The APOL1 was cloned into pDest17 destination vector
containing an N-terminal 66His-tag and transformed into BL21-
AI competent E. coli. Protein expression was induced using 0.1%
L-Arabinose for 16 hours at 37uC. Cells were lysed with
guanidinium lysis buffer pH 7.8 (6 M Guanidine Hydrochloride,
Author Summary
The sub-species of Trypanosoma brucei are important
pathogens of humans and animals in sub-Saharan Africa. T.
b. brucei is not able to infect humans due to sensitivity to
trypanosome lytic factors (TLF) containing the lytic protein
apolipoprotein L1 (APOL1). T. b. gambiense is the most
prevalent human infective sub-species, although there are
two distinct sub-groups of T. b. gambiense that differ
genetically and in terms of their human serum resistance
phenotype stability. How they resist lysis by TLF is
unknown. Previous data indicates that some group 1 T.
b. gambiense parasites are able to avoid lysis due in part to
reduced expression and activity of the gene encoding a
TLF receptor (HpHbR). The authors showed that despite
group 1 T. b gambiense displaying avoidance of some TLF
particles, this sub-species group is resistant to the lytic
protein of TLF, APOL1. This suggests that avoidance is not
the complete story in this sub-species, as previously
theorised. Group 2 T. b. gambiense is also innately resistant
to APOL1 and there is no evidence of avoidance of TLF in
resistant parasites. Group 2 T. b. gambiense variably
displays the human serum resistance phenotype that does
not appear to correlate with expression of HbHpR.
Differences T.b.gambiense Groups 1&2 HS Resistance
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0.02 M Sodium Phosphate, 0.5 M NaCl) for 5 minutes and the
cellular debris removed with a 0.2 mm filter (Sartorius). The cell
lysate was bound to Ni-NTA beads (Invitrogen) for one hour at
pH 7.8 and then washed twice with wash buffer (8 M Urea,
0.02 M Sodium Phosphate, 0.5 M NaCl) at pH 7.8, followed by
two washes at pH 6 and two washes at pH 5.8. Finally, bound
protein was eluted with wash buffer at pH 4. The eluate was
dialyzed overnight against 0.2 M acetic acid and 0.05% Tween20
and concentrated using 10,000MW Vivaspin columns (Sartorius).
Protein purity was estimated using a NanodropH spectrometer
(Nanodrop) and SDS-PAGE. A Western blot using an antibody
raised against an APOL1 peptide (Sigma-Aldrich) was used to
check that the single band present in the purified preparation was
APOL1. Activity of the recombinant protein was determined by its
ability to lyse T. b. brucei. The specific activity of the protein was
estimated using a previously defined method using the amount
protein needed to lyse 50% of the cell within 2 hours [17]. This
value was determined to be 0.143 units/mg, which is comparable
to purified native APOL1, although much lower than an intact
TLF-1 particle that has a specific activity of 83.3 units/mg [39].
Fluorescence microscopy of TLF-1 uptake
TLF-1 was prepared as previously described [10] and the purity
of preparation was verified by both western blot and SDS PAGE
using an APOL1 specific antibody (Sigma-Aldrich). TLF-1 was
labeled with AlexaFluorH488 (Molecular Probes, Invitrogen) using
the manufacturer’s instructions. In control experiments, bovine
HDL of a density comparable to TLF-1 [10] was also AlexaFluor
tagged. Trypanosomes were re-suspended in serum-free HMI9
medium at a concentration of 106 cells/ml and incubated in
10 mg/ml of LysotrackerH (Invitrogen) and 5 mg/ml of the purified
AlexaFluor tagged human TLF-1 [10]. The cells were incubated
at 37uC for 30 minutes, 1, 2 and 4 hours. At each time point, cells
were washed once in serum-free HMI9 medium and fixed by
immersion in chilled 2.5% gluteraldhyde (Sigma-Aldrich) in
phosphate buffered saline for 5 minutes. The cells were re-
suspended in 50% glycerol, 0.1% DAPI, 2.5% DABCO in
phosphate buffered saline (PBS) and spread onto lysine-coated
slides which were then protected with cover-slips sealed using ethyl
acetate.
Slides were imaged using the Deltavision Core system and
SoftWorx package (Applied Precision) with standard filter sets
(DAPI/FITC/Texas-Red and Light transmission). Approximately
30 serial sections through each trypanosome were taken for each
filter. The images were composited and the brightness, contrast
and color levels normalized between samples and exposures using
the ImageJ software package (US National Institute of Health).
Approximately thirty trypanosomes were imaged per time point to
give an indication of the uptake in the population. The Pearson’s
correlation co-efficient between the TLF and LysotrackerH fields
was calculated using the Pearson-Spearman Correlation (PSC)
Plug-in for ImageJ (http://www.cpib.ac.uk/,afrench/coloc.
html).
Fluorescence microscopy of APOL1 uptake
Trypanosomes were re-suspended in HMI9 medium containing
20% fetal bovine serum at a concentration of 106 cells/ml and
incubated in 10 mg/ml of LysotrackerH (Invitrogen) and purified
recombinant APOL1 (5–50 mg/ml). The cells were incubated at
37uC for 4 hours. After this period, cells were washed once in
serum-free HMI9 medium and fixed by immersion in chilled 2.5%
gluteraldhyde (Sigma-Aldrich) in phosphate buffered saline for
5 minutes. The cells were washed once more in chilled PBS and
then re-suspended in PBS with an AlexaFluorH488 His-Tag
antibody (Molecular Probes, Invitrogen). The cells were gently
agitated for 1 hour and then washed twice with chilled PBS and
spread onto slides as described above.
Real-time PCR
Total trypanosome RNA was extracted from approximately
56106 cells using a Qiagen RNAeasyH mini kit following the
manufacturer’s instructions. The RNA was subjected to three
DNase I (Invitrogen) digests to remove all genomic contamination.
OmniscriptH RT Kit (Qiagen) was used to generate cDNA from
1 mg of total RNA as per the manufacturer’s instructions. Real-
time-PCR was performed using cDNA from an equivalent of
50 ng of total RNA, 3 mM forward and reverse primers
(HpHbR_RT_F & HpHbR_RT_R, Table 1) and 12.5 ml of
SYBR green PCR master mix (Applied Biosystems) to a final
volume of 25 ml. Real-time PCR conditions were: one cycle of
50uC for 2 mins, 95uC for 10 mins, followed by 40 cycles of 95uC
for 15 s, 60uC for 1 min. The relative amounts of specific cDNA
between samples were calculated using CT methodology [40]
calculated with the Applied Biosystems SDS v1.4 software. The
endogenous control gene was GPI8 using primers GPI8F and
GPI8R primers (Table 1). Four biological replicates were
performed for each parasite line. All primers were designed using
the Primer3 software [41]. Mean levels of expression were
compared using 1-way ANOVA and Tukey’s post hoc test.
Sequencing and PCR
To test for the presence/absence of SRA and T. b. gambiense
specific glycoprotein (TgSGP) [42], primer sets SRA-F with SRA-R
and TgSGP-F with TgSGP-R [20,37,43] were used to amplify from
prepared genomic DNA. The SRA gene was amplified using the
SRA primer set under the following conditions with Taq
polymerase for 30 cycles; 95uC for 50 seconds, 55uC for
50 seconds and 65uC for 60 seconds while the TgSGP primers
were amplified with the conditions for 30 cycles; 95uC for
Table 1. PCR primers.
Primer Sequence 59-39
HpHbHpr RT F GCCCTATGCTTATGCACATGATC
HpHbHpr RT R ACCTCCGCCAGAGAAAATCTC
GPI8F ATACAACGAATGCGCTGGCC
GPI8R ACCTCCGCCAGAGAAAATCTC
HpHbHpr A F ACAAAGTGGCAGGTGCGTTG
HpHbHpr A R ATT TTC GAT CGG GTT CCC AT
HpHbHpr B F ATG GGA ACC CGA TCG AAA AT
HpHbHpr B R AATCAGTTTTTTAGGGCGGC
ESAG6 F CCGGAATTCGCTATTATTAGAACAGTTTCT
ESAG6 R GTGTTAAAATATATC
ESAG7 F CCGGAATTCGCTATTATTAGAACAGTTTCT
ESAG7 R GCTCTAGACATCACTGCATTTTTTGCTTC
SRA F GACAACAAGTACCTTGGCGC
SRA R CAGCAACCATATTCAGAGCC
TgSGP F TCACGGCCATCAGACGGAGA
TgSGP R GCCATCGTGCTTGCCGCTC
JS2 F GATTGGCGCAACAACTTTCACATACG
JS2 R CCCTTTCTTCCTTGGCCATTGTTTTACTAT
doi:10.1371/journal.pntd.0001287.t001
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50 seconds, 60uC for 50 seconds and 65uC for 90 seconds. Primer
sequences are given in Table 1.
The HpHbR ORF and 1000 bp downstream sequence contain-
ing the 39 UTR were amplified from genomic DNA by PCR using
the following conditions with PFU polymerase for 30 cycles; 95uC
for 50 seconds, 55uC for 50 seconds and 65uC for 120 seconds.
PCR products were ligated into the TOPO PCR 2.1 plasmid
(Invitrogen) and amplified using TOP10 (Invitrogen) competent
cells as per the manufacturer’s instructions. The plasmid was
purified using a Qiagen miniprep kit and sent for DNA sequencing
at DNA Sequencing & Services (MRCPPU, University of Dundee,
www.dnaseq.co.uk) using Applied Biosystems Big-Dye Ver 3.1
chemistry on an Applied Biosystems model 3730 automated
capillary DNA sequencer.
The variable regions of the transferrin receptor genes (ESAG6
and ESAG7) [44,45] were amplified from cDNA prepared as
previously described. Primer sets ESAG6_F & ESAG6_R and
ESAG7_F & ESAG7_R (Table 1) were used under the following
PCR conditions with PFU polymerase for 30 cycles; 95uC for
50 seconds, 55uC for 50 seconds and 65uC for 60 seconds. PCR
products were sequenced as previously described.
Results
Human serum resistance phenotypes of different sub-
species
To investigate human serum resistance/sensitivity in the two
different groups of T. b. gambiense STIB386 (group 2 T. b. gambiense)
and ELIANE (group 1 T. b. gambiense) were compared with each
other and with representative isolates of each of the other sub-
species; STIB247 (T. b. brucei) and Baganzi (T. b. rhodesiense). Strains
were cultured and examined for the presence/absence of the sub-
species specific genes SRA (T. b. rhodesiense specific [46]) and TgSGP
(group 1 T. b. gambiense specific [37]) by PCR amplification in
order to verify their sub-species classification (Figure 1). The SRA
gene was found to be present in the T. b. rhodesiense Baganzi strain
and the TgSGP gene was present in the group 1 T. b. gambiense
ELIANE strain, confirming their sub-species status. The strains T.
b. brucei STIB247 and group 2 T. b. gambiense STIB386 do not
possess either gene (Figure 1). The human serum resistance
phenotype for the T. b. brucei and T. b. gambiense strains were
established by monitoring survival in the presence of human serum
over 6 hours (Figure 2). The group 1 T. b. gambiense strain ELIANE
was always resistant to human serum with 100% survival and the
T. b. brucei STIB247 was always sensitive with a mean survival of
less than 25% (Figure 2). These results confirm the sub-species
classification of each of the strains used in the subsequent
experiments, (as previously described for STIB247, ELIANE and
STIB386 [46]). The marked variation in human serum resistance
phenotype previously described in T. b. rhodesiense is also seen in
group 2 T. b. gambiense. By culturing the strain T. b. gambiense
STIB386 in the presence of 10% human serum in an in vitro system
we selected a population of human serum resistant parasites
(STIB386R; Figure 2). Several clonal populations of the original
STIB386 clone gave a range of human serum resistance
phenotypes of which one sensitive line was chosen that was
consistently sensitive to human serum in continuous culture
without human serum (STIB386S; Figure 2). In order to
demonstrate that the lines were indeed isogenic, a series of four
microsatellite markers that are used routinely to genotype isolates,
Tb5/4, Tb2/20, Tb2/10 and Tb3/1, were amplified using the
conditions previously described [47], giving identical genotypes
(unpublished). Thus isogenic lines of sensitive and resistant
parasites were available for comparison.
Bloodstream expression site analysis
Previous studies indicate that the switching of resistance in T. b.
rhodesiense strains correlated with a change in the variable antigen type
(VAT) [23,24,48,49]. In order to determine if a change in VSG
expression site (ES) has occurred, the ESAG6 and ESAG7 genes are
routinely used as ES markers as they contain polymorphisms that are
associated with each expression site [45,50,51,52]. However, while
these markers are useful forT. b. brucei it is possible that the group 2T.
b. gambiense strain used in our study has a reduced repertoire of ESAG6
and ESAG7 variants compared to T. b. brucei, in a similar manner to
group 1 T. b. gambiense, which has been shown to possess a smaller
repertoire of ESAG6 and ESAG7 than other T. brucei sub-species [53].
The ESAGs of group 2 T. b. gambiense have not been studied in detail,
although an estimate of the variation of ESAG6 and ESAG7 can be
determined from the available genome sequence for this strain
(Berriman, unpublished). The genome sequence for the other sub-
species were also available for analysis: theT. b. brucei strains STIB247
(Berriman, unpublished), the genome reference TREU927 [54] and
the group 1 T. b. gambiense strain DAL972 [55]. Sequence reads were
aligned to the published variants of ESAG6 and ESAG7
[53,54,56,57,58]. Sequence reads from STIB247, TREU927 and
STIB386 aligned to 21, 22 and 22 unique ESAG6 and 21, 22 and 21
unique ESAG7 sequences, respectively (Figure S1). However, the
group 1 T. b. gambiense strain DAL972 [55] sequencing analysis only
showed aligned reads for eight unique ESAG6 sequences and nine
unique ESAG7 sequences. This parallels previously published data
revealing that group 1 T. b. gambiense have a less variable ESAG
complement than T. b. brucei [53]. Alternatively, it may be the case
that group 1 T. b. gambiense has an ESAG complement containing
variants that differ from the T. brucei ESAG6 and ESAG7 sequences
previously published. Whichever hypothesis is correct, both suggest
that the group 2 T. b. gambiense strain STIB386 possess a T. b. brucei-
like rather than a group 1-like ESAG repertoire. This is consistent with
other studies suggesting that group 2 T. b. gambiense are more similar
to T. b. brucei than group 1 T. b. gambiense [59,60] including the
possession of metacyclic ESAGs found in T. b. brucei and T. b.
rhodesiense, but not group 1 T. b. gambiense [57]. These results suggest
that ESAG6 and ESAG7 variants are suitable ES markers.
In order to determine if a switch in ES is associated with the human
serum resistance phenotype in STIB386, we examined the ES used in
both sensitive and resistant lines using ESAG6 and ESAG7 as ES
markers. RNA from both sensitive and resistant isogenic lines was
extracted and used to generated cDNA. The hyper-variable regions
of ESAG6 and ESAG7 genes were then amplified by PCR and
sequenced. No sequence differences were detected between the
hyper-variable regions of ESAG6 and ESAG7 in T. b. gambiense
STIB386S and STIB386R lines. Multiple clones from the PCR
reactions were sequenced confirming that the dominant ESAGs from
the active ES were detected (Figure S2). These results are consistent
with the view that both isogenic lines are using the same dominant
ES, suggesting that human serum resistance in group 2 T. b. gambiense
is not associated with ES switching.
HpHbR expression
Recent evidence indicates that T. b. gambiense group 1 parasites
do not take up TLF-1 due to reduced expression and function of
HpHbR [36]. A reduction of expression of this gene in T. b. brucei
by RNAi or gene knockout confers TLF-1 resistance [13,36]. Do
group 2 T. b. gambiense parasites employ a similar mechanism? To
address this question, the expression of the HpHbR gene was
examined in the different lines by measuring the relative amounts
of transcript for the gene using quantitative real-time PCR. The T.
b. brucei line (STIB247), isogenic lines of T. b. gambiense group 2
(STIB386S and STIB386R) and T. b. rhodesiense (Baganzi) strains
Differences T.b.gambiense Groups 1&2 HS Resistance
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all expressed similar levels of transcript for the HpHbR gene
relative to a GPI8 endogenous control (Figure 3). Expression levels
of the GPI8 control did not show much variation across the
different isolates. The STIB386R strain showed a slight decrease
in mean level of expression of the gene compared to STIB386S
but this was not statistically significant using a one-way ANOVA
(F7= 4.03, p= 0.091). However, the group 1 T. b. gambiense strain
expressed a five-fold lower mean transcript level compared to the
other parasite lines and comparing expression across all five strains
identified a significant difference (F18 = 36.51, p,0.01). Post-hoc
Tukey’s tests indicated the group 1 T. b. gambiense strain ELIANE
to be different to all other lines whilst all comparisons between the
other four lines were not significant.
TLF-1 uptake and localization
In order to determine if group 2 T. b. gambiense parasites have a
functional HpHbR and so take up TLF-1 and traffic the complex
to the lysosome in a similar manner to T. b. brucei, the uptake of
labeled TLF-1 was examined in STIB386S and STIB386R lines in
relation to the other parasite strains. TLF-1 was tagged with
alexafluorH488 and its uptake analyzed by microscopy in
conjunction with the commercial dye LysotrackerH, which labeled
acidic vesicles including the lysosome. As previously reported, no
labeled TLF-1 was detected in the group 1 T. b. gambiense strain
parasites indicating a lack of TLF-1 uptake [36]. However the T. b.
brucei strain STIB247, T. b. rhodesiense strain, Baganzi, and both the
isogenic group 2 T. b. gambiense lines STIB386S and STIB386R
lines all showed internalization of TLF-1 within one hour and co-
localization of the TLF-1 with acidic vesicles (Figure 4). The mean
correlation co-efficients (R) estimating the degree of correlation
between the position of TLF-1 and LysotrackerH were: STIB247,
R= 0.9 (n = 14); STIB386S, R= 0.68 (n = 18); STIB386R,
R= 0.63 (n= 19); Baganzi, R= 0.72 (n= 28). This indicates that
the HpHbR protein of group 2 is functional and that reducing
uptake of TLF-1 is not a potential resistance mechanism for group
2 T. b. gambiense strain STIB386 in contrast to group 1 T. b.
gambiense, which has been shown to not only have reduced
expression of the gene but also a reduced function of the protein
due to several amino acid substitutions within the open reading
frame (ORF) [36]. Sequence analysis of the ORF of the HpHbR
gene revealed several differences in sequence (Figure S3). In order
to investigate if there was a difference in the rate of uptake of TLF-
1 between the different strains, TLF-1 uptake was examined over a
four-hour time course and compared to the uptake of bovine
Figure 1. Identification of sub-species of T. brucei lines. PCR amplification of (A) the SRA gene, (B) the TgSGP gene and (C) microsatellite marker
JS2 as a template control. Track 1 = ladder, track 2 = T. b. brucei STIB247, track 3 = T. b. rhodesiense Baganzi; track 4 =group 2 T. b. gambiense STIB386,
track 5 =group 1 T. b. gambiense ELIANE and track 6 =no template control.
doi:10.1371/journal.pntd.0001287.g001
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HDL. The STIB247, Baganzi and STIB386S lines all took up
TLF-1 rapidly whereas STIB386R took up TLF-1 at a slower rate
that reached an asymptote at approximately 60% (Figure S4). In
contrast, type 1 T. b. gambiense showed no visible uptake of TLF-1
during the four-hour exposure.
Recombinant APOL1 activity, uptake and localization
The knowledge that group 1 T. b. gambiense parasites have
evolved to avoid TLF-1 uptake raises the possibility that this sub-
species group’s resistance strategy is based on avoidance and it is
inherently susceptible to APOL1 mediated lysis. However, this fact
is difficult to reconcile with what is known about TLF-1 and TLF-
2 uptake in these parasites. TLF-1 enters trypanosomes not only
via the HpHbR but also via a low affinity receptor that is as yet
unidentified; therefore a reduction in two TLF-1 receptors is
required for protection from TLF-1. In addition, TLF-2 is
internalized in a different manner to TLF-1 that does not involve
HPR binding [14]. Unfortunately we were not able to work
Figure 2. Human serum resistance phenotype. The survival of parasites exposed to 25% lytic human serum for 6 hours as a percentage of the
starting cell count. Each value is the mean result from a separate experiment (for ELIANE, n = 4). The two isolate populations that were selected to
create T. b. gambiense STIB386S (circled in blue) and T. b. gambiense STIB386R (circled in red) are indicated.
doi:10.1371/journal.pntd.0001287.g002
Differences T.b.gambiense Groups 1&2 HS Resistance
www.plosntds.org 6 September 2011 | Volume 5 | Issue 9 | e1287
Figure 3. Relative HpHbR expression. The relative abundance of transcripts for the HpHbR in each cell line relative to GPI8 as internal control. All
samples were normalized against the mean T. b. brucei strain STIB247 CT value (n = 4 for each line and standard error of the mean CT values is shown).
Statistically significant value (P,0.01) is indicated with an asterisk.
doi:10.1371/journal.pntd.0001287.g003
Figure 4. TLF-1 uptake and localization. The localization of fluorescently tagged TLF-1, LysotrackerH and DAPI after one hour exposure. The
panels represent the following sub-species: T. b. brucei, STIB247; T. b. rhodesiense, Baganzi; T. b. gambiense, STIB386S; T. b. gambiense, STIB386R and
T. b. gambiense, ELIANE.
doi:10.1371/journal.pntd.0001287.g004
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directly with active TLF-2 but it is possible to assay the different
strains for susceptibility to APOL1 using recombinant protein.
Recombinant APOL1 has been shown in numerous experiments
to be toxic to T. b. brucei and is internalized via fluid phase
endocytosis [21,61,62]. Therefore, uptake of this recombinant
protein would be unavoidable. The capacity for recombinant
APOL1 to lyse group 1 T. b. gambiense, in addition to both sensitive
and resistant forms of group 2 T. b. gambiense and T. b. brucei, was
examined for several concentrations of protein. Recombinant
APOL1 is able to lyse T. b. brucei and sensitive group 2 T. b.
gambiense fully after 24 hours. Lysis occurs at even low concentra-
tions of protein, which approach physiological levels [63]. The
resistant group 2 T. b. gambiense strain and the group 1 T. b.
gambiense strain were unaffected by APOL1, even at high
concentrations (Figure 5 and Figure S5). This indicates that the
difference between sensitive and resistant forms of group 2 T. b.
gambiense is not due to differences in uptake but a difference in
sensitivity to APOL1.
Although in other T. brucei lines recombinant APOL1 was
internalized and trafficked to the acidic compartments [21,61,62],
it is possible that the group 1 T. b. gambiense and resistant group 2 T. b.
gambiense are able redirect APOL1 away from these organelles and
avoid APOL1 activation. It is also possible that the recombinant
protein is not being trafficked to the acidic compartments so would
not reach the site of action. To investigate this, the internalization and
location of recombinant APOL1 was visualized in several T. brucei
lines using fluorescence microscopy (Figure 6). All sub-species showed
visible uptake of recombinant APOL1 within four hours. The
position of highest fluorescence correlates with the lysotracker dye,
including the group 1 T. b. gambiense strain ELIANE and the resistant
group 2 T. b. gambiense strain STIB386R. The mean correlation co-
efficient (R) of the recombinant APOL1 and LysotrackerH field was
estimated for each parasite line: STIB247, R=0.87 (n=16);
STIB386S, R=0.81 (n=13); STIB386R, R=0.89 (n=15); Baganzi,
R=0.76 (n=15); ELIANE, R=0.85 (n=18). This would indicate
that both group 1 T. b gambiense and resistant group 2 T. b. gambiense
possess the ability to resist the lytic effects of APOL1 in the lysosome.
These results are in stark contrast to data suggesting TLF-1 shows
reduced uptake in group 1 T. b. gambiense cells over short-term due to
reduced expression and activity of HpHbR.
In summary, T. b. gambiense group 2 parasites appear to express
the HpHbR gene and have a functional protein that facilitates the
uptake of TLF-1, unlike that of T. b. gambiense group 1. These
results indicate that important differences in the cell biology of
human serum resistance exist between the T. b. gambiense group 2
parasites and T. b. gambiense group 1.
Figure 5. Recombinant APOL1 activity. The percentage of viable motile cells measured after 24-hour exposure to various concentrations of
recombinant APOL1 (compared to no APOL1 control) for the T. b. brucei strain STIB247, the resistant & sensitive isogenic lines of the group 2 T. b.
gambiense STIB386 and the group 1 T. b. gambiense ELIANE. Standard error is indicated (n = 2).
doi:10.1371/journal.pntd.0001287.g005
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Discussion
The group 2 T. b. gambiense strain STIB386 exhibits a variable
phenotype as previously described [31,64], but continuous
exposure to a low concentration of normal human serum
maintains the resistant phenotype indefinitely allowing compari-
sons between isogenic sensitive and resistant forms. Analysis of
these parasites indicates that both sensitive and resistant parasites
internalize TLF-1. As resistance to lysis by normal human serum
and TLF-1 correlates with resistance to recombinant APOL1, it
would appear that the resistance mechanism of group 2 T. b.
gambiense is able to either neutralize or compensate for the effects of
the protein. This allows it to overcome both TLF-1 and TLF-2
particles. This is in contrast to group 1 T. b. gambiense parasites that
avoid uptake of the TLF-1 particle. However the innate resistance
of both group 1 and group 2 T. b. gambiense to APOL1 might be
based on the same mechanism. This resistance is distinct from the
SRA gene mediated mechanism in T. b. rhodesiense, although the
mechanism could still involve an inhibitory protein similar to SRA.
Previous attempts to characterize human serum resistance/
sensitivity in group 2 T. b. gambiense have relied on examination of
the TxTat strain [64]. However, some TxTat lines have
subsequently been shown to be T. b. rhodesiense [65]. Examination
of the human serum resistance phenotype in TxTat suggested that
a switch between resistant and sensitive forms was always
accompanied by a switch in variable antigen type (VAT),
indicating that the resistance mechanism is closely related to
antigenic variation [49,64], consistent with these isolates being T.
b. rhodesiense. Our sequencing data show that identical ESAG6 and
ESAG7 gene copies are expressed in both strains of STIB386
suggesting that, irrespective of VSG expression, the same
dominant ES is being used in both sensitive and resistant
populations and that resistance may be unrelated to the use of a
particular ES, as it is in T. b. rhodesiense. While it is intuitive to
assume any variability in expression in trypanosomes is due to
expression site switching, expression stochasticity is a common
feature to many eukaryotes and can arise from several different
mechanisms [66].
As previously reported, the group 1 T. b. gambiense strain
ELIANE does not appear to internalize and concentrate TLF-1 to
any discernable degree over the short term and would appear to
employ an avoidance of uptake strategy to prevent lysis by TLF-1.
This can be explained by both substantial down-regulation and/or
loss of function in the HpHbR involved in internalizing TLF-1
Figure 6. Recombinant APOL1 localization. The localization of Alexa488 labeled anti-pentaHis antibody, LysotrackerH & DAPI after four hour
exposure to recombinant ApoL1 featuring a 66His tag. The panels represent the following sub-species: T. b. brucei, STIB247; T. b. rhodesiense, Baganzi;
T. b. gambiense, STIB386S; T. b. gambiense, STIB386R and T. b. gambiense, ELIANE.
doi:10.1371/journal.pntd.0001287.g006
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[36]. Alternately, TLF-1 may be differentially trafficked by
ELIANE to RAB-11 compartments rather than the lysosome,
rapidly removing the toxic particles from the cell and so would not
be detected in this assay. There are two group 1 T. b. gambiense
specific polymorphisms in the 39 UTR of HpHbR that could
potentially contribute to mRNA instability and reduced expression
of HpHbR to affect short-term uptake of TLF-1. There are also
several polymorphisms in the ORF of HpHbR that appear to affect
the function of HpHbR in group 1 T. b. gambiense [36]. This has
been demonstrated by ectopically expressing the group 1 T. b.
gambiense version of the gene into an artificially selected L427
HpHbR null mutant, resulting in a failure to restore the full TLF-1
sensitivity phenotype [36].
Interestingly, despite several strains exhibiting a loss of function and
expression in the HpHbR receptor [36], group 1 T. b. gambiense appear
to be fully resistant to the lytic effects of recombinant APOL1. Several
hypotheses can be formulated as to why group 1 T. b. gambiense avoid
TLF-1 despite its inherent resistance to APOL1; these include the
hypothesis that the TLF-1 particle evolved before TLF-2 in primates.
T. b. gambiense may initially have evolved primate infectivity by simply
avoiding the TLF-1 particle by modifying receptors for HP/HPR. The
sub-species was then unable to use a similar mechanism to avoid
uptake of TLF-2 as this particle is not internalized in the same manner
[14]. Instead, a second resistance mechanism to counteract APOL1
evolved. Another hypothesis is that the T. b. gambiense resistance
mechanism is dose dependent and by avoiding TLF-1 uptake is able to
avoid the majority of the APOL1 in the human bloodstream. This
would suggest that group 1T. b. gambiensemay be susceptible to APOL1
lysis if internalized at high concentrations.
The results presented here demonstrate some remarkable features of
the variation in human serum resistancemechanisms that have evolved
in trypanosome strains. In Eastern Africa, trypanosomes have evolved
the SRA protein to neutralize APOL1 and resist lysis by TLF.
However, this is not the entire story and some human infective
trypanosome strains in these T. b. rhodesiense foci do not possess the SRA
mechanism [23,67]. The resistance mechanism for these isolates is
unknown. While it has been suggested that avoidance of TLF-1 is a
resistance strategy in the most prevalent human infective trypanosome,
group 1 T. b. gambiense [36], this mechanism is not exhibited by the
related and sympatric group 2 T. b. gambiense suggesting a resistance
strategy that is different. It is now clear that human serum resistance in
both groups of T. b. gambiense involves the ability to either neutralize or
resist the effects of APOL1, although resistance is variably expressed in
group 2. While it may be that groups 1 and 2 T. b. gambiense share a
resistance mechanism, population studies suggest that the two groups
are not closely related [26,27,28,29,30,31,32,33,35,59,68,69,70].
Taking all of the evidence into account, it would appear that human
infectivity has likely evolved in the field on at least four occasions,
suggesting there are multiple ways in which these parasites can avoid
innate immunity. These facts, coupled with the relative ease with which
TLF resistant parasites can be selected from T. b. brucei parasites [71]
indicates that novel human infective parasites could evolve from the T.
brucei population. Understanding the processes involved in overcoming
these factors will aid in the development of novel intervention
strategies.
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